DocDollars

Boehringer Ingelheim International GMBH

Germany · Reporting entity ID 100000005541

Total reported 2019–2025
$211.5M
#57 of 2,960 reporting companies — 0.3% of all reported industry payments
$23.7M in general payments across 10,756 records, plus $187.8M in research funding across 116,638 records.

How it breaks down

General payments $23,700,916
Research funding $187,782,834

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Boehringer Ingelheim International GMBH reported $211.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #57 of 2,960 reporting companies. 89% of that was research funding and 11% general payments such as consulting, speaking, food and travel. 10,756 general payment records and 116,638 research records were filed.

Common questions about Boehringer Ingelheim International GMBH

How much has Boehringer Ingelheim International GMBH paid US doctors?

Boehringer Ingelheim International GMBH reported $211,483,750 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $23,700,916 in general payments, $187,782,834 in research funding.

How does Boehringer Ingelheim International GMBH rank among drug and device companies?

It ranks #57 of 2,960 reporting entities by total reported value, about 0.3% of all industry payments in the dataset.

Does a payment from Boehringer Ingelheim International GMBH mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.